Influence of the depression treatment with escitalopram in mild to moderate arterial hypertension

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

REBEC

Registry ID

RBR-5tzcnw

Enrollment

Unknown

Registered

2014-11-05

Start date

2010-03-01

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

essential (primary) hypertension

Interventions

Active group: 15 persons with high pressure and depression received escitalopram until 20 mg/day for 8 weeks. Control group: 15 persons with high pressure and depression received placebo until 2 capsu

Drug

D27.505.954.427.700.122.050

Eligibility

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 18 to 65 years; arterial hypertension stage 1 or 2; major depressive disorder

Exclusion criteria

Exclusion criteria: Liver insuficiency; cardiac insuficiency, renal insuficiency; secundary arterial hypertension; use of psycotropics; psychotic disorder; alcohol or substances disorder; suicide risk

Design outcomes

Primary

Measure	Time frame
Expected primary outcome: alteration in the follow parameters: systolic arterial pressure times 0 to 4, ; diference in systolic arterial pressure between times 0 to 1 and 1 to 4;Expected primary outcome:dyastolic arterial pressure times 0 to 4; diference in dyastolic arterial pressure between times 0 to 1 and 1 to 4.;Observed outcome: significative fall in the diference of the systolic arterial pressure between times 1 to 4(( ?t1-t4: 20,07± 13,45 mmHgx 9,43± 14,87 mmHg? p=0,04).;observed outcome: there were no statistical difference of the systolic arterial pressure in the following parameters; beginning 139,0mmHg±13,39 x 146,7±11,49 p=0,1; second week 155,4mmHg±16,74 x 153,8±12,44 p=0,77; fourth week 142,0mmHg±16,83 x 142,4±15,65 p=0,94; sixth week 138,1±17,27 x 145,0±14,90 p=0,25; eight week 135,3mmHg±16,40 x144,4mmHg ±13,15 p=0,1; difference between beginning and second week 16,3mmHg ±14,54 x 7,1 ±11,85 p=0,065. ;observed outcome: there were no statistical difference of the dyastolic arterial pressure in the following parameters; beginning 79,1mmHg ±9,66 x 82,1mmHg ±9,79, p=0,41; second week 90,6mmHg ± 12,88 x 85,6mmHg ±9,15 p=0,22; fourth week 86,8mmHg ± 13,02 x 80,4mmHg ±13,71 p=0,2; sixth week 81,3mmHg ± 11,69 x82,0mmHg ±13,24 p=0,88; eight week 80,3mmHg ± 12,80 x 80,6mmHg ± 13,37 p=0,96; difference between beginning and second week 16,3mmHg ±14,54 x 7,1mmHg ± 11,85 p=0,065; difference between beginning and eight week 10,2mmHg ± 6,27 x 5,0mmHg ± 9,41, p=0,089.	—

Measure

Time frame

Expected primary outcome: alteration in the follow parameters: systolic arterial pressure times 0 to 4, ; diference in systolic arterial pressure between times 0 to 1 and 1 to 4;Expected primary outcome:dyastolic arterial pressure times 0 to 4; diference in dyastolic arterial pressure between times 0 to 1 and 1 to 4.;Observed outcome: significative fall in the diference of the systolic arterial pressure between times 1 to 4(( ?t1-t4: 20,07± 13,45 mmHgx 9,43± 14,87 mmHg? p=0,04).;observed outcome: there were no statistical difference of the systolic arterial pressure in the following parameters; beginning 139,0mmHg±13,39 x 146,7±11,49 p=0,1; second week 155,4mmHg±16,74 x 153,8±12,44 p=0,77; fourth week 142,0mmHg±16,83 x 142,4±15,65 p=0,94; sixth week 138,1±17,27 x 145,0±14,90 p=0,25; eight week 135,3mmHg±16,40 x144,4mmHg ±13,15 p=0,1; difference between beginning and second week 16,3mmHg ±14,54 x 7,1 ±11,85 p=0,065. ;observed outcome: there were no statistical difference of the dyastolic arterial pressure in the following parameters; beginning 79,1mmHg ±9,66 x 82,1mmHg ±9,79, p=0,41; second week 90,6mmHg ± 12,88 x 85,6mmHg ±9,15 p=0,22; fourth week 86,8mmHg ± 13,02 x 80,4mmHg ±13,71 p=0,2; sixth week 81,3mmHg ± 11,69 x82,0mmHg ±13,24 p=0,88; eight week 80,3mmHg ± 12,80 x 80,6mmHg ± 13,37 p=0,96; difference between beginning and second week 16,3mmHg ±14,54 x 7,1mmHg ± 11,85 p=0,065; difference between beginning and eight week 10,2mmHg ± 6,27 x 5,0mmHg ± 9,41, p=0,089.

—

Secondary

Measure	Time frame
Expected secundary outcome: alteration in cardiac frequency times 0,1,2,3,4. ;Observed secundary outcome: cardiac frequency time 4 lower on escitalopram group than placebo:escitalopram 66,88 ± 9,62 bpm x placebo 74,19 ± 9,55 bpm, p= 0,04.	—

Countries

Brazil

Contacts

Public ContactMarcello;Marcello Peixoto;Peixoto

Universidade Federal de São Paulo;Marcello Finardi Peixoto

marcello.fp@uol.com.br;marcello.fp@uol.com.br+55(11)34998580;11-34998580

Outcome results

None listed

Source: REBEC (via WHO ICTRP)